WEREWOLF THERAPEUTICS, INC. Research and Development Expense
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Research and Development Expense of $6.16 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $6.16M, a 53.12% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $8.18M, a 37.64% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $6.93M, a 55.92% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $11.63M, a 7.14% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. research and development expense for fiscal 2023 was $41.78M, a 22.29% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. research and development expense for fiscal 2022 was $53.76M, a 52.43% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. research and development expense for fiscal 2021 was $35.27M, a 111.94% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. research and development expense for fiscal 2020 was $16.64M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.16M S-4 · filed 2026-09-22 | $14.34M S-4 · filed 2026-09-22 | $21.28M derived: sum of 3 quarters · filed 2026-09-22 | $32.91M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $8.18M 10-Q · filed 2026-05-07 | $15.11M derived: sum of 2 quarters · filed 2026-09-22 | $26.75M derived: sum of 3 quarters · filed 2026-09-22 | $39.89M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $6.93M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $18.57M derived: sum of 2 quarters · filed 2026-09-22 | $31.71M derived: sum of 3 quarters · filed 2026-09-22 | $44.83M S-4 · filed 2026-09-22 |
| 2025-09-30 | $11.63M 10-Q · filed 2025-11-04 | $24.78M derived: sum of 2 quarters · filed 2026-09-22 | $37.90M 10-Q · filed 2025-11-04 | $53.62M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $13.14M S-4 · filed 2026-09-22 | $26.26M S-4 · filed 2026-09-22 | $41.99M derived: sum of 3 quarters · filed 2026-09-22 | $54.52M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $13.12M 10-Q · filed 2026-05-07 | $28.85M derived: sum of 2 quarters · filed 2026-09-22 | $41.38M derived: sum of 3 quarters · filed 2026-09-22 | $56.65M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $15.73M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $28.25M derived: sum of 2 quarters · filed 2026-09-22 | $43.53M derived: sum of 3 quarters · filed 2026-09-22 | $56.43M S-4 · filed 2026-09-22 |
| 2024-09-30 | $12.53M 10-Q · filed 2025-11-04 | $27.80M derived: sum of 2 quarters · filed 2025-11-04 | $40.71M 10-Q · filed 2025-11-04 | $50.36M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $15.27M 10-Q · filed 2025-08-14 | $28.18M 10-Q · filed 2025-08-14 | $37.83M derived: sum of 3 quarters · filed 2025-08-14 | $48.67M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $12.91M 10-Q · filed 2025-05-08 | $22.56M derived: sum of 2 quarters · filed 2025-05-08 | $33.40M derived: sum of 3 quarters · filed 2025-05-08 | $42.98M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $20.49M derived: sum of 2 quarters · filed 2025-03-11 | $30.07M derived: sum of 3 quarters · filed 2025-03-11 | $41.78M 10-K · filed 2025-03-11 |
| 2023-09-30 | $10.84M 10-Q · filed 2024-11-07 | $20.42M derived: sum of 2 quarters · filed 2024-11-07 | $32.13M 10-Q · filed 2024-11-07 | $47.99M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $9.58M 10-Q · filed 2024-08-08 | $21.29M 10-Q · filed 2024-08-08 | $37.15M derived: sum of 3 quarters · filed 2024-08-08 | $50.22M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $11.71M 10-Q · filed 2024-05-03 | $27.57M derived: sum of 2 quarters · filed 2024-05-03 | $40.63M derived: sum of 3 quarters · filed 2024-05-03 | $54.52M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $28.93M derived: sum of 2 quarters · filed 2024-03-07 | $42.82M derived: sum of 3 quarters · filed 2024-03-07 | $53.76M 10-K · filed 2024-03-07 |
| 2022-09-30 | $13.07M 10-Q · filed 2023-11-14 | $26.96M derived: sum of 2 quarters · filed 2023-11-14 | $37.90M 10-Q · filed 2023-11-14 | $51.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $13.89M 10-Q · filed 2023-08-10 | $24.83M 10-Q · filed 2023-08-10 | $38.23M derived: sum of 3 quarters · filed 2023-08-10 | $48.02M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $10.95M 10-Q · filed 2023-05-11 | $24.34M derived: sum of 2 quarters · filed 2023-05-11 | $34.13M derived: sum of 3 quarters · filed 2023-05-11 | $41.40M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $23.19M derived: sum of 2 quarters · filed 2023-03-23 | $30.45M derived: sum of 3 quarters · filed 2023-03-23 | $35.27M 10-K · filed 2023-03-23 |
| 2021-09-30 | $9.79M 10-Q · filed 2022-11-10 | $17.05M derived: sum of 2 quarters · filed 2022-11-10 | $21.87M 10-Q · filed 2022-11-10 | $27.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $7.26M 10-Q · filed 2022-08-11 | $12.08M 10-Q · filed 2022-08-11 | $17.37M derived: sum of 3 quarters · filed 2022-08-11 | $22.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.82M 10-Q · filed 2022-05-10 | $10.10M derived: sum of 2 quarters · filed 2022-05-10 | $14.91M derived: sum of 3 quarters · filed 2022-05-10 | $18.70M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $10.10M derived: sum of 2 quarters · filed 2022-03-24 | $13.88M derived: sum of 3 quarters · filed 2022-03-24 | $16.64M 10-K · filed 2022-03-24 |
| 2020-09-30 | $4.81M 10-Q · filed 2021-11-10 | $8.59M derived: sum of 2 quarters · filed 2021-11-10 | $11.36M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.78M 10-Q · filed 2021-08-12 | $6.54M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $2.76M 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |